Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Considerations for First-Line Metastatic Melanoma: Which Treatment Is Best?

Updated Data for First-Line Immunotherapy Combinations Reinforce Their Value in Metastatic Melanoma

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity, Journal for ImmunoTherapy of Cancer

Actualizaciòn en el tratamiento de metàstasis cerebrales por melanoma

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - The Lancet Oncology

Cancers, Free Full-Text

OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy in Metastatic Melanoma

Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. - Document - Gale OneFile: Health and Medicine

Updated Data From Clinical Trials on Nivolumab/Ipilimumab in Advanced Melanoma - The ASCO Post

Nivolumab + Ipilimumab Shows Efficacy for Untreated Brain Mets